Drug intelligence / Profile preview

upadacitinib + ustekinumab

Development stage: Unknown
Lead developer: AbbVie
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous, Subcutaneous

Overview

Dual-targeted therapy combining upadacitinib (a selective JAK1 inhibitor) and ustekinumab (an IL-12/IL-23 inhibitor) used primarily for treating refractory Crohn's disease and patients with co-existing extraintestinal manifestations. This combination approach targets multiple inflammatory pathways simultaneously and has shown efficacy in patients who have failed multiple previous biologic therapies.

Brand names: Stelara (ustekinumab)Wezlana (ustekinumab)Imuldosa (ustekinumab)Otulfi (ustekinumab)Pyzchiva (ustekinumab)Rinvoq (upadacitinib)

Targets

IL-23 (Interleukin-23)JAK1 (Janus kinase 1)

Beyond the preview

Go deeper on upadacitinib + ustekinumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on upadacitinib + ustekinumab.

Explore the full profile